Increasing incidence of resistance to nalidixic acid in shigellas from humans in England and Wales: implications for therapy

被引：12

作者：

Cheasty, T ^{[1
]}

Day, M ^{[1
]}

Threlfall, EJ ^{[1
]}

机构：

[1] Hlth Protect Agcy, Specialist & Reference Microbiol Div, Lab Enter Pathogens, London NW9 5HT, England

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2004年 / 10卷 / 11期

关键词：

dysentery; nalidixic acid; quinolones; resistance; Shigella; therapy;

D O I：

10.1111/j.1469-0691.2004.00982.x

中图分类号：

R51 [传染病];

学科分类号：

100401 [流行病与卫生统计学];

摘要：

Among shigellas isolated from patients in England and Wales in 2002, 10% of subgroups A, B and C, and 13% of subgroup D (Shigella sonnei), were resistant to nalidixic acid. As a consequence, should antimicrobial therapy be indicated, the efficacy of nalidixic acid as the preferred treatment for children with bacillary dysentery has been jeopardised.

引用

页码：1033 / 1035

页数：4

共 8 条

[1]

Is it time to change fluoroquinolone breakpoints for Salmonella spp.? [J].